Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ironwood Pharmaceuticals (IRWD) Long-Term Debt Repayments (2016 - 2024)

Ironwood Pharmaceuticals' Long-Term Debt Repayments history spans 11 years, with the latest figure at $15.0 million for Q4 2024.

  • For Q4 2024, Long-Term Debt Repayments fell 40.0% year-over-year to $15.0 million; the TTM value through Dec 2024 reached $65.0 million, up 160.0%, while the annual FY2024 figure was $65.0 million, 35.0% down from the prior year.
  • Long-Term Debt Repayments for Q4 2024 was $15.0 million at Ironwood Pharmaceuticals, up from -$150.0 million in the prior quarter.
  • Across five years, Long-Term Debt Repayments topped out at $175.0 million in Q2 2024 and bottomed at -$150.0 million in Q3 2024.